Skip to main content

Adult Growth Hormone Deficiency Clinical Trials

Understanding Long-Term Use of Sogroya® in Adults With AGHD

Living with Adult Growth Hormone Deficiency?

Learn About an Observational Study Today! 

Adult Growth Hormone Deficiency (AGHD) is a rare but serious condition characterized by the inadequate secretion of growth hormone (GH) in adults. This can lead to increased body fat, decreased muscle mass, reduced bone density, insulin resistance that can lead to Type 2 diabetes, and diminished quality of life. Unlike growth hormone deficiency in children, which affects development, AGHD primarily impacts physical function and metabolic health in adults.

Revival Research Institute is conducting an observational study for adults with Adult Growth Hormone Deficiency (AGHD) who are already prescribed Sogroya®. This study aims to better understand the long-term safety and real-world outcomes of Sogroya® use in routine clinical practice.

Are You Eligible to Participate?

To be eligible for our Adult Growth Hormone Deficiency clinical trials, individuals must meet the following criteria:

  • Male or female, age ≥18 years
  • Diagnosis of adult growth hormone deficiency (AGHD) as per local practice
  • Patient and physician decided to start Sogroya® (somapacitan) treatment independently and prior to study participation

*Additional criteria may apply.

Participation in this observational study involves completing study-related assessments while continuing the Sogroya® treatment prescribed by your healthcare provider. The study helps researchers better understand real-world use and long-term safety outcomes in adults with AGHD. 

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Who is this information for?**

Please provide YOUR contact information only.

Name*
Best Time to Call*
User Agreement*

This is our Privacy Policy.

About the Clinical Trials for Adult Growth Hormone Deficiency

Living with Adult Growth Hormone Deficiency (AGHD) can take a real toll on your daily life. It can lead to persistent fatigue, increased body fat, reduced muscle mass, and low energy levels, all of which affect overall well-being.

Revival Research Institute is conducting a long-term, observational clinical study to gather real-world safety data on Sogroya® (somapacitan), a once-weekly growth hormone therapy already prescribed to adults with AGHD. This study focuses on understanding long-term outcomes, especially around potential risks like type 2 diabetes and tumor formation. 

This observational study will be conducted at multiple locations across the United States, including Texas. To determine eligibility, all participants will complete a screening process. Individuals who qualify will take part in study-related assessments while continuing the Sogroya® treatment prescribed independently by their healthcare provider. No study medication is provided as part of this research. 

*All study-related procedures are provided at no cost to participants. This observational study does not include study medication, and participants must continue using Sogroya® as prescribed independently by their healthcare provider. Compensation may be available for time and travel.

*To take the next step, submit the form above, and our research staff will contact you to determine if you qualify for the study. A brief discussion about your health and medical history may be required.

Get Started: What to Expect?

If you are living with adult growth hormone deficiency, you may qualify for an observational study designed to better understand the long-term, real-world use of Sogroya® in adults with AGHD. After completing the interest from above, a research team member will contact you for a brief pre-screening to see if you meet the initial eligibility criteria. If you qualify, you will be asked to review and sign an Informed Consent Form (ICF), which explains all study procedures, potential benefits, and risks.

Following your consent, you’ll be invited to a screening visit at our clinical research site. During this initial visit, we will ask questions about your medical history, perform physical exams, and run lab tests to further assess your eligibility. If you meet all study requirements, you may be able to participate in this observational study. 

Our team will ensure you fully understand your role in the study and what to expect throughout the process. You are encouraged to ask any questions before enrolling. Your participation contributes to research aimed at better understanding long-term, real-world outcomes for adults living with AGHD who are already prescribed Sogroya®.

Age

≥18 Years

Condition

Adult Growth Hormone Deficiency

Location

Texas

Understanding Adult Growth Hormone Deficiency

About Adult Growth Hormone Deficiency

AGHD can be caused by:

  • Pituitary tumors or surgery
  • Traumatic brain injury
  • Radiation therapy
  • Autoimmune inflammation
  • Idiopathic causes (no known cause)

Symptoms of AGHD include:

  • Decreased muscle mass and strength
  • Increased abdominal fat
  • Fatigue and low energy
  • Impaired psychological well-being
  • Elevated cholesterol and cardiovascular risk
  • Poor sleep and cognitive function

Adults diagnosed with AGHD typically receive growth hormone therapy and routine medical follow-up as part of their standard care. This observational study does not provide treatment but collects information about the real-world use and long-term safety of Sogroya® in individuals already prescribed this medication. 
 

Frequently Asked Questions (FAQs)

What is adult growth hormone deficiency?

AGHD is a condition in which the pituitary gland fails to produce adequate levels of growth hormone in adulthood. It can develop after childhood or occur due to damage to the hypothalamic-pituitary axis.

What causes AGHD?

Common causes include pituitary tumors, traumatic brain injury, surgery, radiation therapy, and autoimmune conditions. Some cases have no identifiable cause and are considered idiopathic.

How is AGHD diagnosed?

AGHD is diagnosed through hormone stimulation testing, such as the insulin tolerance test (ITT) or glucagon stimulation test. These tests assess the pituitary gland’s ability to secrete growth hormones.

What are the treatment options for AGHD?

Treatment for AGHD is prescribed and managed independently by a person’s healthcare provider. This study does not provide treatment or make changes to a participant’s medical care. 

Why should I participate in this study?

Participating in this observational study helps researchers better understand the real-world, long-term use of Sogroya® in adults with AGHD who are already prescribed the medication. Your involvement may contribute valuable information that supports future medical research. Study-related assessments may be provided, and compensation may be available for time and travel. 

We are dedicated to advancing medicine & redefining patient care, one clinical trial at a time — with compassion. We are Revival’s Site Network spanning across Michigan, Texas, Nebraska, Georgia, Arizona & Illinois.

Quick Links

Quick Links

Contact Info

  • 28270 Franklin Road, Suite F
    Southfield, MI 48034
  • 248-721-9539
Close Menu







    Your information is confidential and used only for study enrollment purposes.








      Your information is confidential and used only for study enrollment purposes.








        Your information is confidential and used only for study enrollment purposes